Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison to BCG in Healthy Volunteers in South Africa

This study has been completed.
Sponsor:
Collaborators:
Farmovs-Parexel Bloemfontein, Republic of South Africa (Clinical Site)
Triclinium Johannesburg, RSA (Monitoring and Overall Management of the study)
University of Stellenbosch
HJ-CTC George, RSA (Statistics & Report)
Information provided by (Responsible Party):
Vakzine Projekt Management GmbH
ClinicalTrials.gov Identifier:
NCT01113281
First received: April 27, 2010
Last updated: November 18, 2011
Last verified: November 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2011
  Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)